Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Luye Pharma Group ( (HK:2186) ) has shared an update.
Luye Pharma Group Ltd. announced the conversion of US$25,000,000 of its Tranche A Bonds at a conversion price of HK$3.672 per share. This move is part of the company’s ongoing financial strategy involving US$100,000,000 5.85% convertible bonds due in 2025, which may impact its financial structure and investor relations.
The most recent analyst rating on (HK:2186) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, primarily engaged in the development, production, and sale of innovative pharmaceutical products. The company focuses on the global market, with a particular emphasis on the Chinese market.
Average Trading Volume: 106,358,790
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.49B
For detailed information about 2186 stock, go to TipRanks’ Stock Analysis page.